<DOC>
	<DOCNO>NCT00153582</DOCNO>
	<brief_summary>In trial , HLA-A2+ patient active AML vaccinate peptide leukemia-associated antigen WT1 together immunological adjuvant keyhole limpet hemocyanin ( KLH ) T-helper protein granulocyte macrophage colony stimulate factor ( GM-CSF ) 4 time bi-weekly , monthly .</brief_summary>
	<brief_title>WT1 Peptide Vaccination Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>In phase II trial HLA-A2+ patient active AML without curative treatment option vaccinate WT1 126-134 peptide mixed adjuvant KLH T-helper protein GM-CSF 4 time bi-weekly , monthly .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>AML myelodysplastic syndrome ( MDS ) Partial response ( PR ) complete response ( CR ) smolder course without option allogeneic stem cell transplantation HLAA2+ WT1expression bone marrow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>